Keywords: fda, rezulin, withdrawal, study, sees, communication, problems
US FDA Rezulin withdrawal study sees communication, other problems, at CDER
Article | 22 November 2000
An internal US Food and Drug Administration evaluation of the decisionto withdraw Warner-Lambert's diabetes drug Rezulin (troglitazone: Marketletter March 27) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
